In the past year or so, mankind is charting a new path. It's shifting from drugs for acute illnesses to chronic therapies such as diabetes and heart disease. This segment not only gives them more pricing power, but the revenues are also more predictable. But it's still not an easy shift to make. And does mankind have the ability to make that shift?
In today's episode for 22nd April 2023, we talk about Mankind Pharma's IPO.
Tech stocks like Infosys, TCS and others have witnessed a major drop of late, and we decided to delve deeper into what's really happening.
In our latest video by Shrehith Karkera- co founder at Finshots, we discuss all this and more. So go check it out right now on Shrehiths YouTube channel - https://www.youtube.com/watch?v=H-9WlbrW0Bo